Yea Christopher's Form 4 filing
KalVista Pharmaceuticals, Inc. (KALV) · filed Feb 21, 2024
- Accession no.
- 0001415889-24-004716
- Filed
- Feb 21, 2024
- Trade date
- Feb 17-20, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market sales total $170.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yea ChristopherCIK 0001691102 | Officer (CHIEF DEVELOPMENT OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2024 | Common Stock | MOption exerciseDisposed | −1,774 | $0.00 | $0 | 15,964 | Direct | |
| Feb 17, 2024 | Common Stock | MOption exerciseDisposed | −2,430 | $0.00 | $0 | 17,014 | Direct | |
| Feb 17, 2024 | Common Stock | MOption exerciseDisposed | −7,292 | $0.00 | $0 | 7,292 | Direct | |
| Feb 17, 2024 | Common Stock | MOption exerciseDisposed | −7,292 | $0.00 | $0 | 29,167 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Referenced by the price of 1 transaction in Table I.
- F3
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.7503 to $14.1289 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.